focus -WSS

focus

author：entertainment 2025-10-06 08:54:52 - browse：38585

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Why a market frenzy over new weight loss drugs defies logic

WSS

Judge rejects Trump's request to move Stormy Daniels hush

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Roche acquires Telavant from Roivant, adding experimental IBD treatment

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Affordable Connectivity Program vital to health care, experts say

Divers poised to search for children washed away in Pennsylvania flash flood

Wikipedia

focus

hotspot

Drug repurposing or repositioning? The language matters

Why a market frenzy over new weight loss drugs defies logic

ChatGPT in medicine: STAT answers readers' burning questions

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

The cancer drug shortage isn’t new — and neither are the solutions

Tocagen's brain cancer gene therapy trial continues. Investors worry

Anesthesiologist group: stop taking Ozempic before surgery

Awakening the world to the whoosh: A patient's crusade

Continuity nursing helped my family in our darkest PICU moments

Merck, Daiichi strike cancer drug pact worth up to $22 billion

hotspot

Awakening the world to the whoosh: A patient's crusade

Study on Amgen’s bispecific immunotherapy produces positive data

Study identifies new proteins linked to dementia risk 25 years later

UnitedHealth, Optum discontinue NaviHealth name

UnitedHealth, Optum discontinue NaviHealth name

Readout LOUD podcast: Live from the 2023 STAT Summit

Wikipedia

focus

knowledge

entertainment